Specialty Pharmacy

A new report suggests Amazon is in talks with Mylan and Sandoz.

Another study suggests gut bacteria has an important role in triggering multiple sclerosis.

The FDA previously found that PD-1/PD-L1 inhibitors may increase the mortality risk for patients with multiple myeloma.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses the importance of specialty pharmacists becoming certified and how it improves the industry as a whole.

Pharmacy professionals must embrace a number of changes in technology.

Independent pharmacies must stay on top of developing trends across the specialty pharmacy landscape.

The CVS-Aetna acquisition could have several implications for pharmacies and patients.

Genetically engineering the gut microbiome may hold the key to treating Crohn’s disease.

Top news of the day from across the health care landscape.

Centers for Medicare & Medicaid Services proposed national coverage determination of the FoundationOne CDx test.

Ixekizumab found to provide significant improvement in joint symptoms for patients not previously treated with a biologic disease-modifying antirheumatic drug.

Evolocumab (Repatha) is the only PCSK9 inhibitor approved to prevent heart attack, stroke, and coronary revascularization.

FDA plans to further expedite novel treatments under the 21st Century Cures Act.

A second HIV test may avoid significant costs.

Development of tirasemtiv halted due to poor performance in a late-stage clinical trial.

Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.

Joel Wright, chief executive officer, AllianceRx Walgreens Prime discusses how specialty pharmacies can leverage retail pharmacies connections to negotiate costs.

Top news of the day from across the health care landscape.

Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.

Strategic tips for pharma to develop an overall business strategy around digital engagement.

Trastuzumab-dkst (Ogivri) is the second biosimilar approved for cancer.

Patients with a partner were nearly twice as likely to finish 6 months of chemotherapy for colon cancer.

Moses Zonana, CEO of Compliance Meds Technologies, discusses the impact of medication nonadherence.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Raltegravir (Isentress) is an integrase inhibitor for use in combination with other antiretroviral agents for HIV-1 in newborn infants weighing at least 2 kg.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.